We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clopidogrel Response in Acute Ischemic Stroke. The Bochumer CRISP Study (Bo-CRISP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01843361
Recruitment Status : Completed
First Posted : April 30, 2013
Last Update Posted : April 30, 2013
Sponsor:
Information provided by (Responsible Party):
Saskia Meves, Ruhr University of Bochum

Brief Summary:
The aim of this study was to determine the prevalence rate and risk factors for chemical laboratory clopidogrel low-response (CLR) in the acute phase after an ischemic stroke.

Condition or disease
Ischemic Stroke

Study Type : Observational
Actual Enrollment : 159 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Prevalence of Low Response to Clopidogrel in Patients After Acute Ischemic Stroke.
Study Start Date : July 2010
Primary Completion Date : December 2012
Study Completion Date : December 2012

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Group/Cohort
acute ischemic stroke
Determing cardiovascular risk factors or medication on clopidogrel response rates after an acute ischemic stroke



Primary Outcome Measures :
  1. Result of platelet function test [ Time Frame: one day ]
    Aggregometry result of antiplatelet therapy



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with an acute ischemic stroke admitted to our stroke unit and treated with clopidogrel
Criteria

Inclusion Criteria:

  • acute ischemic stroke
  • admittance to stroke unit
  • clopidogrel medication

Exclusion Criteria:

  • no consent
  • prior bleeding disorders
  • severe liver disorders
  • current gastrointestinal disorders
  • congestive heart failure
  • life-threatening malignancies

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01843361


Locations
Germany
Department of Neurology, Ruhr University Bochum
Bochum, Germany, 44791
Sponsors and Collaborators
Ruhr University of Bochum
Investigators
Principal Investigator: Saskia H Meves, MD Ruhr University Bochum, Department of Neurology

Publications:
Responsible Party: Saskia Meves, MD, Ruhr University of Bochum
ClinicalTrials.gov Identifier: NCT01843361     History of Changes
Other Study ID Numbers: Meves-clopi-01
First Posted: April 30, 2013    Key Record Dates
Last Update Posted: April 30, 2013
Last Verified: April 2013

Keywords provided by Saskia Meves, Ruhr University of Bochum:
Stroke
Clopidogrel
Aggregometry
Antiplatelet therapy
Platelet function tests

Additional relevant MeSH terms:
Stroke
Ischemia
Cerebral Infarction
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes
Brain Infarction
Brain Ischemia
Clopidogrel
Ticlopidine
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Fibrinolytic Agents
Fibrin Modulating Agents
Cytochrome P-450 CYP2C19 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors